GSK becomes latest member of FDI’s Vision 2020 partnership

30 April 2018 Vision 2020

GlaxoSmithKline (GSK) is the latest partner to join the Vision 2020 family, FDI’s advocacy strategy to strengthen the position of oral health by improving its awareness and visibility at both the national and global level.

"I am delighted to have a science-led global healthcare company like GSK supporting our ambitions in oral health advocacy. With Vision 2020 as our compass and our new three-year strategy in place, we have a real opportunity to lead global advocacy efforts to increase oral health literacy and achieve political commitment and action on oral health in all countries. We thank our partners for their continued trust and encouragement."
Dr Kathryn Kell, FDI President 

"Joining FDI’s Vision 2020 advocacy strategy is an opportunity to demonstrate GSK’s commitment to oral health. We look forward to working with FDI to promote acceptance among policymakers that oral health is both an essential component to general health and well-being."
Dr Stephen Mason, Oral Health Category Medical Director at GSK 

Vision 2020: FDI’s advocacy strategy

FDI’s advocacy strategy, known as Vision 2020, establishes a platform for oral health action over the next three years (2018-2020). It provides an overview of oral health successes, challenges, and opportunities, outlining the priorities that will be pursued to improve oral health. These priorities are encapsulated by three goals that will guide FDI’s work over the period of the strategy as follows:

  • Ensuring that oral health is recognized and accepted as a core element of general health and well-being;
  • Integrating oral health into the prevention and treatment of other noncommunicable diseases (NCDs); and
  • Mobilizing members to build national capacity to effectively influence and shape oral health priorities on a global scale.

Launched in 2012 to map the challenges facing the oral health community, Vision 2020 was conceived as a blueprint to shape the future of oral health. From 2013 to 2016, FDI’s national-level advocacy efforts were known as Vision 2020 and global activities were performed independently. In 2016, national and global advocacy efforts were consolidated under Vision 2020 to strengthen FDI’s advocacy approach. Vision 2020 is now FDI’s official advocacy strategy.

An advocacy strategy was developed in 2016 and carried out until 2017 – the same year that FDI’s organizational strategic plan ended – to implement Vision 2020’s global and national advocacy activities.

GSK joins 3M, GC, Henry Schein, Ivoclar Vivadent, Morita, Unilever and Wrigley in the group of partners supporting FDI’s Vision 2020.

About GlaxoSmithKline

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit

Find out more...